		Type: <b>Drug Guideline</b>	Document reference: <b>6343</b>	Manual Classification: <b>Waikato DHB Drug Guidelines</b>
Title: <b>Chlorothiazide for Neonates</b>			Effective date: <b>21 October 2020</b>	
Facilitator <small>sign/date</small>  <i>Kerrie Knox Pharmacist</i>	Authorised <small>sign/date</small>  <i>Jutta van den Boom Clinical Director NICU</i>	Authorised <small>sign/date</small>  <i>John Barnard Chair Medicines &amp; Therapeutics</i>	Version: <b>1</b>	Page: <b>1 of 2</b>
			Document expiry date: <b>21 October 2023</b>	

© Waikato DHB, November 2020

## BRIEF ADMINISTRATION GUIDE

**Note:** Chlorothiazide is **NOT catalogued** in The Australasian Neonatal Medicines Formulary (although a similar thiazide diuretic [hydrochlorothiazide](#) is). Please refer to the [NZ formulary for children](#) for further information.

- Indications:**
- Treatment of mild to moderate fluid overload states including congestive heart failure, mild to moderate hypertension, ascites and bronchopulmonary dysplasia
  - Adjunct therapy to diazoxide in the management of hyperinsulinaemic hypoglycaemia
  - Treatment of central and/or nephrogenic diabetes insipidus

**Route:** Oral

- Supplied as Chlorothiazide 50 mg/mL oral suspension, 25 ml bottle (Chlorothiazide is an unregistered medicine available under section 29 of the Medicines Act. Names of the patient and prescriber must be sent to Pharmacy when ordering.)

**Dose:**

Diuresis

10 – 20 mg/kg/dose twice daily

May be used in combination with spironolactone for its potassium sparing effects.

Hyperinsulinaemic hypoglycaemia

3 – 5 mg/kg/dose twice daily

Diabetes insipidus

10 mg/kg/dose twice daily

### Preparation and administration


- Shake suspension well before use
- Draw up prescribed dose in an oral syringe
- Administer prescribed dose orally with feeds to minimise gastrointestinal irritation

### Monitoring

- Monitor blood pressure daily for 4 days when starting or changing dose
- Monitor fluid balance
- Monitor renal function at baseline and periodically during therapy
- Monitor serum electrolytes, calcium, phosphorus and glucose at baseline and periodically during therapy

### Storage and Stability

- Store chlorothiazide oral suspension in the fridge, between 2 – 8 °C
- Once opened discard after 7 days

	Document reference: <b>6343</b>	Effective date: <b>21 Oct 2020</b>	Expiry date: <b>21 Oct 2023</b>	Page: <b>2 of 2</b>
	Title: <b>Chlorothiazide for neonates</b>	Type: <b>Drug Guideline</b>	Version: <b>1</b>	Authorising initials:

## Competency for Administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management certification.

## References

- New Zealand Formulary for Children (NZFC). 2018. Chlorothiazide. Accessed 24<sup>th</sup> August 2020. Available from: [https://www.nzfchildren.org.nz/nzf\\_1009](https://www.nzfchildren.org.nz/nzf_1009)
- Truven Health Analytics Inc. Pediatrics and Neofax®. Chlorothiazide monograph. Accessed 24<sup>th</sup> August 2020. Available from: <http://www.micromedexsolutions.com>.
- Lexicomp. Chlorothiazide: Pediatric drug information monograph. Uptodate. Accessed 26<sup>th</sup> September 2018. Available from: <https://www.uptodate.com>.
- Ainsworth SB. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life 7<sup>th</sup> ed. John Wiley & Sons Incorporated; 2014.
- BNF for children. 2018-2019. Chlorothiazide monograph.
- Auckland DHB Newborn Services. Chlorothiazide Drug Protocol. May 2013. Available from: <http://www.adhb.govt.nz/newborn/DrugProtocols>
- Canterbury DHB Neonatal Services. Spironolactone Drug Information Sheet. June 2012. Available from: <http://www.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets>.
- Salix Pharmaceuticals Inc. Chlorothiazide Oral Suspension Data Sheet. Accessed 26<sup>th</sup> September 2018. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/011870s0401bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011870s0401bl.pdf)

**Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.**

**Disclaimer:** *This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.*